还没做过化疗，EGFR是野生型的病友一定要去做ALK的检测

jzjqian 发表于 2012-7-25 15:45

                               
登录/注册后可看大图

请教，像我这样的，手术22个月了，还能去原手术医院拿到病理作EGFR检查么？

3 i1 T- u6 C9 d可以，但要有针对性，

请问，肺鳞癌，只做过一次化疗，骨髓抑制严重，后吃特罗凯4个月基本无效，可以参加实验组吗？

不可以了,要没做过任何治疗的,包括化疗和靶向药

Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
9 l, ?3 ]: @3 M% `

Sub-category:
Molecular Targets


5 q$ R% A: s  c/ [' U  \) }Category:
4 J' }! ]+ W  f& C" o) FTumor Biology
5 ]/ j! m# o2 x, d$ d& U
9 w9 x/ X5 S2 R8 `2 c% I0 v) J7 c
2 D, U# |3 m2 J2 D4 j; PMeeting:
2011 ASCO Annual Meeting


Session Type and Session Title:
! ^1 ^9 ^9 D% y' f5 }Poster Discussion Session, Tumor Biology
/ Q# Z5 @# |6 e0 P; W1 O
: S% a. P3 L0 }+ M
8 A" z" q+ h  w" X1 dAbstract No:
3 n1 W2 t3 i! k0 W0 A) }6 A/ l10517

/ k9 v# p4 X- N9 ~# I
Citation:
8 V( z0 ?& n2 e: H: UJ Clin Oncol 29: 2011 (suppl; abstr 10517)
' J7 P  c5 Q6 z; T( C
0 C/ n9 K7 L3 a: W$ I
5 [+ ?$ V7 K' d" K; mAuthor(s):
1 V% s* X+ j4 Z  y3 y* w) }# cJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
+ g' J# s4 ~! M8 a1 T1 s6 }
! c+ N$ V3 ^2 C4 r! V. f0 C$ P
  W' N2 U# a+ t8 `; g/ X$ I& ]
3 L! N5 o# d0 G: A1 V1 LAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
6 \6 {2 t6 g* e% G( ]
Abstract Disclosures

7 t) {7 I" I0 ?/ a3 a. E2 {Abstract:

" c' {; R* c9 o! x& `% p+ _" s
1 \- m) r2 q  f' f7 t, _Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
% X7 ?! ~9 t; q

3 i4 h* ]. _1 @  s) M+ @  J

由吴一龙教授牵头的A80810029临床试验上周启动，初诊未治疗的晚期肺腺癌患者检测到ALK阳性，可参加一线crizotinib 对比力比泰+卡铂的临床研究，药物全部免费，即使分配到力比泰组，疾病进展之后可免费获得crizotinib.

没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

boeun 发表于 2012-11-18 16:37

# w7 l- n0 X! \) e: M& b; m" h1 D0 W                               
登录/注册后可看大图

没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

4 S( b  B/ \; Z8 w5 ]4 `9 F化疗过的没机会了

平安！ 发表于 2012-7-20 11:20

                               
登录/注册后可看大图

易瑞沙、特罗凯有效的病人基本上可以断定ALK（-）。极其罕见EGFR、ALK同时突变的。
1 j( X/ f; Z6 o" t- {ALK一个指标医院要900多 ...

平安，真的没有希望吗？我弟弟虽然特罗凯有效，但是ＥＧＦＲ是野生型，不是突变啊。有没有必要去检测ＡＬＫ呢？
4 D! b* {3 ~/ v, v/ W
现在病情进展，快没招儿了。

好像想加入挺困难的

小地方没条件做啊